No big money investors yet but I am pretty certain we have a lot of new small investors who will be holding for success, the win-win. That is when Cell-in-a-Box(R)'s technology goes to market and its value is realized in the pps. Fewer traders and more investors, imo.

Following the science, that is the key for investors . The day to day pps is the concern for traders.

Let the new investor decide if that is true...

Studies already begun for diabetes, first round for malignant ascites completed with good results last year and now an extended study with 13 treatments for malignant ascites is to begin within 2 weeks of January 26...

http://money.cnn.com/news/newsfeeds/articles/marketwire/11G032301-001.htm

http://www.nasdaq.com/press-release/pharmacyte-biotechs-expanded-followup-study-on-malignant-ascites-fluid-accumulation-in-final-stage-20150126-00537

Yeahright, I think it is pretty evident that things are getting pretty exciting and good things are coming. Our DD tells us that. Besides, our CEO has kept us very informed. No need to be an insider to know where this company is headed.

Nonetheless, the technology was proven before and is being proven again under the leadership of Dr Von Hoff and his team at TD2. Additionally, Dr Von Hoff found an entirely new use for Cell in a Box(R)'s technology which showed success in the first study. We are preparing for an extended study for 13 treatments addressing malignant ascites. And then, we will move into Phase I/II with a current ODD. And we already know we will apply to fast track this technology to get to patients faster.

Investor, lots of DD here and in the iBox... Below are previous trial results and info on current studies.


http://www.mdpi.com/1999-4923/6/3/447

http://globenewswire.com/news-release/2015/01/26/699897/10116902/en/PharmaCyte-Biotech-s-Expanded-Follow-up-Study-on-Malignant-Ascites-Fluid-Accumulation-in-Final-Stages-of-Preparation.html?print=1

http://money.cnn.com/news/newsfeeds/articles/marketwire/11G032301-001.htm

SIAL (NASDAQ) trading at over $137 a share right now is in the business of selling biological products and kits. And unless the average consumer is doing medical research, I think Amazon does not have a market for their products.

However, at $137 a share, I imagine there many Biotechs who use their products which bodes well for Cell in a Box technology.

"Sigma-Aldrich Corporation is an American life science and high technology company with over 9,600 employees and operations in 40 countries.[4] Its chemical and biochemical products and kits are used in scientific research, biotechnology, pharmaceutical development, the diagnosis of disease, and as key components in high technology manufacturing.[5]"

http://www.sigmaaldrich.com/technical-documents/articles/biology/cell-in-a-box.html

B Free, never saw that page before. Great DD, thanks...

Great Pete, I have added the link to my file. :)

BTW, I'd like to publicly thank you for all you do. The iBox is very well done...


http://www.mdpi.com/1999-4923/6/3/447

PMBC is pretty straight forward. They have not misrepresented themselves at all. They have told us the first study results were good which is evidently true with the start of a second extended study.

It is evident fooling people is a goal of some. Fortunately, we offer much DD already done to help those decipher who is potentially deceptive and who is not.

Pretty easy process and we have a very smart group of investors.

One definition is "around the corner". Just means it is coming...

Trials Austrianova conducted with CiaB are public information and provided below.

Mice Studies are not publicized. You cannot be so impatient with a biotech. Once trials begin after the studies, they will be available to the public...

PMBC is the company so, since the study results are not public, we should not expect to hear anything from anyone else.

This is really not so mysterious and par for the course. It just works like this newmixer. PMBC Is not going to reinvent the process. Studies are not publicized, CEOs provide shareholder updates...

http://austrianova.com/wp-content/uploads/2014/08/pharmaceutics-06-00447-v2.pdf

I will let you and others worry about the current pps. I am following the science. The pps is volatile until we reach a few more milestone... Imminent

Not true. The science was proven so much in last year's study with TD2 that Dr Von Hoff and his team are now going to start an expanded study for 13 different treatments in preparation for human trials. Pretty significant science in my opinion.

"To our knowledge, there is no other treatment on the market that can accomplish this - particularly in the case of advanced cancers."

PharmaCyte Biotech's Expanded Follow-up Study on Malignant Ascites Fluid Accumulation in Final Stages of Preparation

SILVER SPRING, Md., Jan. 26, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box®, today reported that preparations for an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of low doses of the cancer prodrug ifosfamide and Cell-in-a- Box® capsules containing live cells capable of converting ifosfamide into its cancer-killing form) on the accumulation of malignant ascites fluid are in their final stages. This preclinical study will be conducted by Translational Drug Development (TD2) in the United States. Pancreatic cancer expert Dr. Daniel D. Von Hoff is the Chief Development Officer of TD2 and a principal architect of the study. It is expected that the study will begin in approximately two weeks.

This expanded study is designed to build upon the successful results of the pilot study that was completed by TD2 late last year. In that study, mice bearing an aggressive human ovarian cancer (ES-2), which produces significant amounts of malignant ascites fluid, were divided into 4 groups with 10 mice in each group. The mice in Group 1 served as a control group. Group 2 was made up of mice treated with PharmaCyte Biotech's pancreatic cancer treatment. Group 3 was treated with cisplatin, a chemotherapy drug often used to treat ovarian cancer. Group 4 was treated with a combination of PharmaCyte Biotech's pancreatic cancer treatment and cisplatin.

The new expanded study will use the same ES-2 ovarian cancer model, but in this study, the mice will be divided into 13 different treatment groups with 10 mice in each group. This study is designed to better define the parameters that will be needed to design a future Phase 1 clinical trial in humans that suffer from malignant ascites fluid accumulation as a result of their abdominal cancers, such as pancreatic, liver, ovarian, uterine and colon.

Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, said, "We are looking forward to this expanded preclinical study of the effectiveness of our pancreatic cancer treatment in reducing the rate of malignant ascites fluid accumulation in the abdomen. If successful, it could quickly lead to a clinical trial in patients with abdominal tumors who suffer from this very serious cancer-associated malady. The accumulation of ascites fluid is problematic for patients with an abdominal cancer because it's very painful and can cause breathing problems. Once it gets to a certain stage, it must be removed on a regular basis. This procedure in itself is very uncomfortable for patients and costly. Hopefully, our pancreatic cancer treatment will slow the accumulation of this malignant ascites fluid and thus reduce the number of withdrawals of the fluid that are needed over a given period of time. To our knowledge, there is no other treatment on the market that can accomplish this - particularly in the case of advanced cancers."

http://www.nasdaq.com/press-release/pharmacyte-biotechs-expanded-followup-study-on-malignant-ascites-fluid-accumulation-in-final-stage-20150126-00537

This top Dr was pretty excited to be working with Cell in a Box(R) technology and the first study went so well, we are now doing an expanded study. I will follow this guys lead. After all, he has gotten FDA approval already and also served as an advisor to the FDA.

"The Nuvilex team presents us with a new tool to employ against the symptoms and invasive properties of this very challenging cancer," said Daniel D. Von Hoff, M.D., Chief Development Officer of TD2. "Our Pancreatic Cancer Research Team (PCRT) colleagues are enthusiastic to begin clinical trials with this approach."

http://www.nasdaq.com/press-release/pharmacyte-biotechs-expanded-followup-study-on-malignant-ascites-fluid-accumulation-in-final-stage-20150126-00537

http://www.td2inc.com/news/nuvilex-selects-translational-drug-development-td2-to-advanc

We certainly have no control over the pps, that is why I focus on the science. That is stability. The pps is obviously volatile for many different reasons. That will change when the science is proven for both malignant ascites, diabetes and multiple forms of cancer. I hope the pps continues to be a dissappointment for shorts. I will be here when it does fly and never look back.

It will be a while but I can wait.

Simply not true. We longs do our DD here. They are selling it for sure but only since June 2014. This is another milestone I attribute to our CEO who takes his mission very seriously. He got this done after only 8 months on the job of course with the help of Autrianova's executives, two of whom now work for PharmaCyte, Drs Gunzburg and Salmons

Sigma-Aldrich Corporation (SIAL) To Launch Austrianova's Cell-In-A-Box® Kit for Research Use

June 5, 2014 -- Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and High Technology company recently named to the “Global 100 Most Sustainable Corporations in the World”, will shortly be releasing one of its latest research products for sale: a kit for hand-driven, self-encapsulation of cells which was designed by the Singapore based biotech company Austrianova and uses their proprietary Cell-in-a-Box® technology.

Austrianova conceptualized this novel approach for lab-scale encapsulation of any kind of living cells which is the first product of its kind to be available on the market. Brian Salmons, CEO of Austrianova commented, “The idea behind the kit was to leverage on the global distribution network of Sigma-Aldrich® to provide researchers and companies alike with the ability to undertake early stage tests at low cost and without the need for specialized equipment and training.”

John Dangerfield, COO of Austrianova, responsible for development of the kit with his team at Austrianova’s R&D facility in Singapore, added that, “The Sigma-Aldrich® Kit allows Cell-in-a-Box® technology to be used in the lab to look at cell viability, cellgrowth and release of biomolecules from the capsules as well as more practical aspects such as cryopreservation for storage and transport”.

Austrianova should be contacted directly concerning manufacturing for downstream preclinical and clinical applications.

http://www.biospace.com/News/sigma-aldrich-corporation-to-launch-austrianovas/336052

Thanks for a great post and very nice to hear from you. :)

Yeahright, no need to make Pete a believer. You know who you are and that is what matters. In the end, true longs will be here for a while and your loyalty will be evident. So hard to tell anyone's real intentions. Believe me, everyone is suspect. I think we all have been suspect to one or another person's... :)

Hang in there... This is a long term investment...

I agree. It's like a Cancer with a cure but we have no one to help us because we are on the OTC. They all know it. I have also seen companies no longer on the OTC that shorts have followed and continue to short.

I don't know the answer to that issue short of SEC intervention and with all the businesses they have to oversee, PMCB is out of their scope, I am sure.

That is why I follow the science. The shorts are most concerned about the pps right now. Longs can wait for the proven science to effect the pps.

Unfortunately, I no longer get excited about movement in pps. As soon as we see light a short will write an article to scare away investors.

Our best hope, imo, is to have investors who know and ignore the source of such efforts and are interested in and follow the science.

As long as we attract traders, they complain about how long it is taking and focus on everything but the science.

The good news here bill, is that I see a lot of very astute new investors joining our efforts. That is what we need to control volatility, imo.

Absolutely and we all know the source would certainly not come from those interested in the company's success. We need stability not volatility. It's a no brainer and only those who could care less about the efforts of this company would be interested in this kind of trading environment.

Yep, bunch of shorts, most likely trying to make a penny. Just business as usual on the OTC. Unfortunately businesses trying to make a difference like PharmaCyte are subject to these short pump and dump attempts.

Follow the science not these articles written by folks that don't even interview the company, declare themselves as short and are not written by reputable persons or entities.

Sounds like some shorts trying to get a pump. We stand on the science itself. News from the company about studies is all that is required of longs. Personally, these artificial attempts are more harmful than good and everyone knows that, especially those at PharmaCyte who are all about taking care of the business at hand. Like all of us longs know, the pps will eventually reflect the value of Cell-in-a-Box(R) technology.

Well you know this site does not do their homework. PMCB is on the QB, not the BB. Claims like these need to come from reputable sites to be taken seriously.

The FDA and SEC seem to think highly of PharmaCyte Biotech. FDA granted ODD and the SEC approved a CT order. Each requires a review of the company.

The least this site could do is get the company placing correct.

Again, investor beware of disreputable claims. Follow the science. This is where the company is going.

http://www.otcmarkets.com/stock/PMCB/quote

http://www.pharmaceutical-business-review.com/news/pharmacyte-begins-first-preclinical-study-of-encapsulated-cell-product-for-new-diabetes-treatment-030215-4503058

http://www.nasdaq.com/press-release/pharmacyte-biotechs-expanded-followup-study-on-malignant-ascites-fluid-accumulation-in-final-stage-20150126-00537

And we will continue to show proof for the investors who may just occasionally drop in. I sincerely care about Cell in a Box(R)'s success and want to help in any way possible to thwart these unwarranted attacks.

Investors must beware and do your own DD.

Actually, I think the website has succeeded in its efforts to scare away investors. After all, that is their intent. Pure manipulation, plain and simple.

Investor beware! Red flags all over this website.

http://www.goodetrades.com/2012/05/leslie-howard-is-now-a-stock-promoter/

http://globenewswire.com/news-release/2013/10/04/578298/10051324/en/BluForest-Inc-Temporary-Injunction-and-Court-Order-Entered-Against-George-Sharp-and-Pumps-and-Dumps-com-for-Alleged-Completely-False-Defamatory-Claims-and-Statements.html

Is this a trustworthy website? The information I have about this website makes it sound like it is one used expressly for the purposes discussed earlier about naked shorts needing to affect the pps through manipulation.

Just calling a company a pump and dump will scare some away even with no valid evidence.

Let the individual investor decide if they believe the claims of this suspect website...

In fact, the below story actually made it to Nasdaq. Huge red flags! Hope no one is being duped by these claims.

http://globenewswire.com/news-release/2013/10/04/578298/10051324/en/BluForest-Inc-Temporary-Injunction-and-Court-Order-Entered-Against-George-Sharp-and-Pumps-and-Dumps-com-for-Alleged-Completely-False-Defamatory-Claims-and-Statements.html

http://www.goodetrades.com/2012/05/leslie-howard-is-now-a-stock-promoter/

You will never convince me that Ken Waggoner has been anything other than a blessing to this company. The question is "What have you done lately?" All good for me Ken.

I am not concerned at all. Cell in a Box(R) technology trumps all your concerns for me and Ken has demonstrated outstanding corporate citizenship from my perspective.

However, I do understand there is a need to make him look bad to deter interest in what PharmaCyte is attempting to accomplish.

I just hope the typical PMCB investor is astute enough to see what is evident with PMCB today...

Studies and a heavy hitting team of medical professionals supporting this technology...

We did hear from Dr Von Hoff. He and his team at TD2 want to do an expanded study that is to begin about 2 weeks from Jan 26th.

A bio is no place for those in a rush. Same thing at every bio, studies and trials take a while but the offset is the potential for treatments that help patients which provide for real shareholder gains.

PharmaCyte Biotech's Expanded Follow-up Study on Malignant Ascites Fluid Accumulation in Final Stages of Preparation

SILVER SPRING, Md., Jan. 26, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box®, today reported that preparations for an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of low doses of the cancer prodrug ifosfamide and Cell-in-a- Box® capsules containing live cells capable of converting ifosfamide into its cancer-killing form) on the accumulation of malignant ascites fluid are in their final stages. This preclinical study will be conducted by Translational Drug Development (TD2) in the United States. Pancreatic cancer expert Dr. Daniel D. Von Hoff is the Chief Development Officer of TD2 and a principal architect of the study. It is expected that the study will begin in approximately two weeks.

This expanded study is designed to build upon the successful results of the pilot study that was completed by TD2 late last year. In that study, mice bearing an aggressive human ovarian cancer (ES-2), which produces significant amounts of malignant ascites fluid, were divided into 4 groups with 10 mice in each group. The mice in Group 1 served as a control group. Group 2 was made up of mice treated with PharmaCyte Biotech's pancreatic cancer treatment. Group 3 was treated with cisplatin, a chemotherapy drug often used to treat ovarian cancer. Group 4 was treated with a combination of PharmaCyte Biotech's pancreatic cancer treatment and cisplatin.

The new expanded study will use the same ES-2 ovarian cancer model, but in this study, the mice will be divided into 13 different treatment groups with 10 mice in each group. This study is designed to better define the parameters that will be needed to design a future Phase 1 clinical trial in humans that suffer from malignant ascites fluid accumulation as a result of their abdominal cancers, such as pancreatic, liver, ovarian, uterine and colon.

Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, said, "We are looking forward to this expanded preclinical study of the effectiveness of our pancreatic cancer treatment in reducing the rate of malignant ascites fluid accumulation in the abdomen. If successful, it could quickly lead to a clinical trial in patients with abdominal tumors who suffer from this very serious cancer-associated malady. The accumulation of ascites fluid is problematic for patients with an abdominal cancer because it's very painful and can cause breathing problems. Once it gets to a certain stage, it must be removed on a regular basis. This procedure in itself is very uncomfortable for patients and costly. Hopefully, our pancreatic cancer treatment will slow the accumulation of this malignant ascites fluid and thus reduce the number of withdrawals of the fluid that are needed over a given period of time. To our knowledge, there is no other treatment on the market that can accomplish this - particularly in the case of advanced cancer."

And before the first study, these were his thoughts...

"The Nuvilex team presents us with a new tool to employ against the symptoms and invasive properties of this very challenging cancer," said Daniel D. Von Hoff, M.D., Chief Development Officer of TD2. "Our Pancreatic Cancer Research Team (PCRT) colleagues are enthusiastic to begin clinical trials with this approach."

http://www.nasdaq.com/press-release/pharmacyte-biotechs-expanded-followup-study-on-malignant-ascites-fluid-accumulation-in-final-stage-20150126-00537#ixzz3Qi6irmlO

http://www.td2inc.com/news/nuvilex-selects-translational-drug-development-td2-to-advanc

That would be pretty amazing. Keep us posted.

Here are some more realistic potentials as they directly relate to the company. The potentials that you mentioned can apply to almost any company on the OTC. Fortunately the QB is more regulated than the BB or pinkies and regulation does offer some protection.

We are looking to treat Cancer and diabetes and realize profits as a result of those successes. This is the company's objective and it is long term. Others seem to have short term goals.

Btw, legitimate news on legitimate websites with more realistic potentials...

Each person can decide for themselves.

http://www.nasdaq.com/press-release/pharmacyte-biotechs-expanded-followup-study-on-malignant-ascites-fluid-accumulation-in-final-stage-20150126-00537

http://www.pharmaceutical-business-review.com/news/pharmacyte-begins-first-preclinical-study-of-encapsulated-cell-product-for-new-diabetes-treatment-030215-4503058

It is what it is Alydyr. The company is doing all the right things and yet it is under constant attack. Short interest, especially naked short interest hurts a company as the naked shorts need to cover so they manipulate the market to get the price they need to cover. It's in black and white and not a good thing for a company. It is kind of like a Cancer, imo. Eating away at the PPS for personal gain. Just my opinion from what I have learned over the past year.

I think it is important to recognize this fact because it is now evident that other forces are at play here and their goal is not to help the company with its ventures but actually benefit from its failures so those failures have to be drummed up in ways to get those who know no better to believe. Like the SA articles.

Each person can decide for themselves if it is the company, as is often suggested or naked short positions that is effecting the pps.

That is a significant difference to make because if the company is taking care of its operations, which I believe they are, the pps will improve organically with each significant milestone reached. We just have to ride out the manipulation. Every person has a right to look at it from all angles. Just sharing what I have learned and suspected for a while.

This article explains a little more about my concerns...

http://ajrarchive.org/Article.asp?id=4911

According to this Report, naked short interest was almost 60% for the one month time frame from December 16 to January 15.

http://www.pharmaceutical-business-review.com/news/pharmacyte-begins-first-preclinical-study-of-encapsulated-cell-product-for-new-diabetes-treatment-030215-4503058

And here is info on naked short selling. Sounds more like hedge fund involvement which would explain a lot imo... According to this info, naked short selling requires som manipulation of stock price to cover. Four Seeking Alpa articles bashing the company in two weeks that could not recover from them enough for the faied attempted pump articles that were mixed in there paid by a third party. And all this blamed on the company which dies not benefit from an instable pps. They are trying to treat Cancer and diabetes...

http://www.investopedia.com/terms/n/nakedshorting.asp

http://www.investopedia.com/articles/optioninvestor/09/naked-short-selling.asp

How is naked shorting insignificant? Isn't it illegal?

If it is true that they are naked shorting because they believe this company is illegitimate, I now agree, they could potentially be in big trouble, imo. The company is legit and Cell in a Box(R) will be proven in the near future. I am not worried about them, they hurt the company with naked shorting, not to say it is also illegal, but in the end, there are a lot of believers and from my guess, some do have deep pockets. Two clinical studies this quarter... Malignant ascites and diabetes... Believers and non-believers... Time will tell if this is real or not, not sure what happens if they don't cover, hopefully, they have it figured out...

Great info... So how would you interpret this short interest report that is provided biweekly?

It was actually higher in January than it has been in months but the days to cover is less...

When I did the math very quickly, the daily Volume was about 2.5m from 1/8 to1/15. That makes short interest almost half of the trades. Why so high after the name change?

Thanks

Avg daily vol Days to cover
Jan 15, 2015 1,343,930 2.16 2,251,856 1.00 No No
Dec 15, 2014 2,329,382 -52.17 1,707,930 1.36 No No
Nov 28, 2014 4,870,341 -1.99 1,745,328 2.79 No No
Nov 15, 2014 4,969,020 -1.58 1,124,046 4.42 No No
Oct 31, 2014 5,048,828 -15.82 1,709,553 2.95 No No
Oct 15, 2014 5,997,491 -26.40 1,599,117 3.75 No No
Sept 30, 2014 8,148,256 -3.81 2,324,747 3.51 No No
Sept 15, 2014 8,471,061 0.25 1,278,163 6.63 No No
Aug 29, 2014 8,450,144 -2.56 1,769,292 4.78 No No
Aug 15, 2014 8,672,510 -1.68 1,295,924 6.69 No No

http://www.otcmarkets.com/stock/PMCB/short-sales

Pretty powerful post!

36% short interest is still pretty high. That is more than 1/3 of the trades today...

I would be concerned if this information was not coming from the CEO. Ken does a good job of keeping shareholders up to date on company ventures.